Revenue rose 32.7% and net profit surged 48.6% year-over-year, driven by strong sales in nutrition and vitamins, improved margins, and robust overseas growth. The company advanced its methionine project, completed a major asset sale, and maintained a stable dividend policy.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.